Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @NatResCancer
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @NatResCancer
-
Prikvačeni tweet
What's going on in cancer at Nature Research? Check out https://www.nature.com/collections/bpwtvhdwgf … , and sign up for our weekly e-alerts to receive highlights direct to your inbox!
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
NatResearchCancer proslijedio/la je Tweet
A new article
@NatureCancer from Rubén Pio Lab@CIMA_unav shows intermittent fasting synergizes with PD-1 blockade to inhibit lung cancer progression and metastasis. Please read the full article here article: https://www.nature.com/articles/s43018-019-0007-9 …pic.twitter.com/cHo5Lb6rrF
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
NatResearchCancer proslijedio/la je Tweet
A year ago today I announced that we were creating
@NatureCancer to lend a new voice to the#cancerresearch community and help in the fight against cancer#IAmAndIWill
#WorldCancerDay
https://youtu.be/MPaHlb6826w Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
NatResearchCancer proslijedio/la je Tweet
Interested in an editorial career with
@NatureComms in the field of#immunology? We are now hiring a new associate or senior editor, to be based in London or New York. Learn more & apply before Feb 17: https://go.nature.com/36BwJSq pic.twitter.com/qercxe5dbg
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
NatResearchCancer proslijedio/la je Tweet
For
#WorldCancerDay2020
#WorldCancerDay
@SpringerNature has compiled a variety on contents from many leading journals in the field https://www.springernature.com/gp/researchers/campaigns/oncology-cancer-research …@NatRevClinOncol we have included the inspiring story of@ros1cancerhttps://www.nature.com/articles/s41571-019-0314-1 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
NatResearchCancer proslijedio/la je Tweet
A Review in Nature Reviews Immunology summarizes current knowledge of the roles of B cells and antibodies in the tumour microenvironment. https://go.nature.com/2GB0wjP pic.twitter.com/XbSL5xcYC4
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
NatResearchCancer proslijedio/la je Tweet
When applied retrospectively to a a phase III trial, a system for ctDNA with filtering of alterations from matched white blood cells predicted recurrence when applied within 9 weeks after preoperative treatment and surgery in patients with gastric cancer:https://www.nature.com/articles/s41467-020-14310-3?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NRRJ_2_SJB_nrclinonc_editorial_socialposts …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
NatResearchCancer proslijedio/la je Tweet
Join us at
#HCINatureTCI20 with@huntsmancancer &@NatureRevCancer! Register by Feb 29 for a discounted price: https://umarket.utah.edu/um2/hcisymposium/ …pic.twitter.com/RLtFD2DqK5
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
NatResearchCancer proslijedio/la je Tweet
In
@NatureCancer, Brid Ryan@Sanjusinha7@NCIResearchCtr demonstrate higher frequency of homologous recombination deficiency in tumours from African Americans than European Americans - call for diverse pop'ns in cancer genomics studies#ResearchHighlight https://go.nature.com/31aTKuu pic.twitter.com/TXaPNP4YA8
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
NatResearchCancer proslijedio/la je Tweet
500 followers, lovely! I'm always trying to reach more people to help spread the word about cancer genetics and epigenetics. I'm based
@NatureComms , working closely with@NatureGenet@NatureMedicine@NatureCancer@nature and all the gangPrikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
NatResearchCancer proslijedio/la je Tweet
Transformable peptide nanoparticles, which self-assemble into micelles under aqueous conditions but on binding to HER2 on cancer cells transform into nanofibrils that disrupt HER2 dimerization, arrest HER2 signalling and cause cancer cell death in vivo:https://www.nature.com/articles/s41565-019-0626-4?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NRRJ_2_SJB_nrclinonc_editorial_socialposts …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
NatResearchCancer proslijedio/la je Tweet
wonderful deep dive on intra-tumour heterogeneity in liver cancer- fascinating interplay of spatio-temporal immune/cancer cell interactions
@augustoNYC@craig_mandy@JohannvonFelden@Teresaglezana@TischCancer@MountSinaiNYC@SinaiGenetics@IcahnInstitutehttps://www.nature.com/articles/s41467-019-14050-z …Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
NatResearchCancer proslijedio/la je Tweet
Online at
@nature: “Tobacco smoking and somatic mutations in human bronchial epithelium” by Peter Campbell and colleagues https://www.nature.com/articles/s41586-020-1961-1 … and News and Views: https://www.nature.com/articles/d41586-020-00165-7 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
NatResearchCancer proslijedio/la je Tweet
In our FEBRUARY issue out NOW we have all of this: the PI3K–AKT signalling network in
#cancermetabolism; the ageing microenvironment in tumour progression; fluids & mechanics of metastatic dissemination; dietary patterns &#cancer risk https://go.nature.com/2GyeYJi@NatResCancerpic.twitter.com/QROqXyDchG
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
NatResearchCancer proslijedio/la je Tweet
ATACseq and scRNAseq in chronic lymphocytic leukaemia shows temporal response to ibrutinib. Fascinating paper!
#CancerResearch#chromatinhttps://www.nature.com/articles/s41467-019-14081-6 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
NatResearchCancer proslijedio/la je Tweet
#Free for 1 month: Towards a comprehensive catalogue of validated and target-linked human enhancers https://go.nature.com/2O6ezSC#Review by@MollyGasp, Jacob Tome &@JShendurepic.twitter.com/UrHlGDaOJe
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
NatResearchCancer proslijedio/la je Tweet
A new paper in
@NatureMedicine by Dr. Kochenderfer and colleagues at@NCIResearchCtr supports the idea that we can design and improve CAR T-cell therapies to have fewer negative effects for patients.https://www.nature.com/articles/s41591-019-0737-3 …Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
NatResearchCancer proslijedio/la je Tweet
Tests of thousands of drugs not originally developed for oncology across 578 human cancer cell lines reveals growth-inhibitory effects and provides a way to identify drugs with the potential to be repurposed for cancer, according to a
@NatureCancer paper. https://go.nature.com/2sOKSy1 pic.twitter.com/up8rlo2R9a
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
NatResearchCancer proslijedio/la je Tweet
Last week, the FDA approved the EZH2 inhibitor tazemetostat as the first treatment option specifically for advanced-stage epithelioid sarcoma, which accounts of <1% of soft-tissue sarcomas, based on an ORR of 15%, with 67% of responses lasting >/=6 months:https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-option-specifically-patients-epithelioid-sarcoma-rare-soft-tissue …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
NatResearchCancer proslijedio/la je Tweet
Our
#openaccess Consensus Statement provides a framework for advancing our understanding of cancer-associated fibroblasts authored by 29 leaders in the field! Why not have a read here....https://go.nature.com/2vs60uX@NatResCancer@CSHL@cshlbanburypic.twitter.com/pe5UNwbLWz
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
NatResearchCancer proslijedio/la je Tweet
@NatRevClinOncol is a subscription journal but we can provide you with a shareable link to read the inspiring story of the ROS1ders https://rdcu.be/b0Lox@ESchattner@jamesian@merelhennink@JFreemanDaily@ros1cancer (You will not be able to download but can read and share)Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.